Using PET imaging to predict immunotherapy success in lymphoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates how effective PET imaging targeting granzyme B can predict the outcomes for patients with diffuse large B-cell lymphoma (DLBCL) undergoing immunotherapy. Participants will be numbered and their medical records will be created, documenting essential information such as age, gender, and medical history. Each participant will undergo a PET scan using a 68Ga-grazytracer both at the start and after one course of immunotherapy, which may include CAR-T, Glofitamab, or iR2. The goal is to determine the correlation between granzyme B levels and treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologic diagnosis of DLBCL
2. Patient's general condition is good and survival is expected to be greater than six months
3. Signed and dated informed consent form

Exclusion Criteria:

1. Combined with other malignant tumors
2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
3. Pregnant women and women at risk of pregnancy, breastfeeding women
4. poor compliant

Where it's running

• Ruijin Hospital Affiliated to Shanghai Jiao Tong University Medical School
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xinyi Zhu
• Email: zxy16zz@163.com
• Phone: 19121913585

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Glofitamab combo vs Rituximab combo with chemo for relapsed/refractory DLBCL

  This study tests whether glofitamab with chemotherapy (JS203-GemOx) helps patients with relapsed or refractory DLBCL more than rituximab with chemotherapy.

  Recruiting Phase 3 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality · NCT07808827

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• External beam radiation followed by bispecific antibody therapy for relapsed or refractory DLBCL

  This study tests whether giving targeted radiation first, then bispecific antibodies (epcoritamab or glofitamab), is tolerable for adults with relapsed or refractory diffuse large B-cell lymphoma.

  Recruiting Phase 1 University of Utah · Salt Lake City, Utah · NCT07528352

• Chidamide maintenance for MRD-positive double-expressor DLBCL in first remission

  This study tests whether giving chidamide as maintenance therapy can help people with double-expressor DLBCL who have complete remission but still have MRD detected in their blood.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07507318

• Cognitive changes in people treated for diffuse large B‑cell lymphoma

  This study tests whether adults with newly diagnosed diffuse large B‑cell lymphoma experience cognitive changes during and after standard chemotherapy.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07443514

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.